Olema Pharmaceuticals opened lower at $7.88, compared with its previous close of $8.04. In the last trading session, the stock traded between $7.66 and $8.02. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Olema Pharmaceuticals is now worth
$ 27.73
Resulting in a loss of
$ 72.27 (72.27%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.53 (-6.57%)
Day High
$8.02
Day Low
$7.66
Day Open
$7.88
Prev Close
$8.04
Volume
17,22,425
1W Return
-0.42%
1M Return
2.09%
3M Return
-28.16%
6M Return
-49.45%
1Y Return
-8.28%
Fundamentals
Market Cap ($ Mn)
658
PE Ratio
-
PB Ratio
2.09
PEG Ratio
-
ROE
-42.22%
ROCE
-46.19%
EPS (TTM)
$-0.84
Investment Returns
1 Week
-0.42%
1 Month
2.09%
3 Months
-28.16%
6 Months
-49.45%
9 Months
-68.24%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Olema Pharmaceuticals Q3 Results: Loss widens 49% YoY to $(0.73)
Reported Q3 loss of $(0.73) per share. Missed analyst consensus estimate of $(0.63) by 17.74%. Losses widened 48.98% YoY from $(0.49) per share.
2 days ago
4Nov
Olema Oncology grants stock options to ten new employees
Olema Pharmaceuticals granted stock options for 261,300 shares to ten new employees. Exercise price set at $7.07 per share, matching the November 2, 2026 closing price. Options vest over four years with 25% cliff and monthly thereafter. Grants made under the 2022 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
9 days ago
3Oct
Olema Oncology grants stock options to six new employees
Olema Pharmaceuticals granted options for 235,950 shares to six new employees. Exercise price set at $8.27 per share based on October 1, 2026 closing price. Options vest over four years with 25% cliff vesting at one year. Grants issued under the 2022 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
1mo ago
12Aug
Olema stock falls 12.9% as Q2 loss widens to $63.2M on R&D spend
Olema Pharmaceuticals' Q2 loss widened to $63.2M due to high R&D spend, causing shares to drop 12.9%. Key trial data is delayed to early 2027, but analysts maintain Buy ratings with an average target of $43.00.
3mo ago
3Jul
Olema Oncology grants 215,800 stock options to new employees
Olema Pharmaceuticals, Inc. granted 215,800 stock options to eight new employees effective July 1, 2026, under its 2022 Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $12.08 per share, a 10-year term, and vest over four years. The grants were approved by the Compensation Committee to induce employment with the company.
